Clinical Research Directory

Inclusion Criteria: * Adult women aged 18-75 (both fertile and post-menopausal) * Vulvovaginal atrophy diagnostic * Signed written informed consent. * Vaginal Ph more than 4.5 * Willing to sign the informed consent form * Willing to comply with the clinical investigation visits. Exclusion Criteria: * patients who tend to develop hypertrophic scarring, * patients with a history of autoimmune disease or who are receiving immune therapy, * patients who are known to be hypersensitive or allergic to hyaluronic acid and other INNEA AQUA components, * pregnant or breastfeeding women, * patients under 18 years of age, * vagina with hypertrophic scars from different etiology, * patients with presence of ≥ stage 2 apical pelvic organ prolapse, * patients with stress urinary incontinence, * patients with vaginismus, vulvovaginal or urinary tract infection, * patients with Hemorrhagic or neoplastic genital pathologies or hormone-dependent tumor * patients with genital bleeding of unknown etiology, recurrent porphyria, uncontrolled epilepsy, heart conduction disorders, recurrent angina, rheumatic fever, previous vulvovaginal or uro-gynecological surgery, and hemostatic disorders, * Anticoagulated patients or patients receiving platelet aggregation inhibitors should not be treated with INNEA AQUA, * INNEA AQUA must not be used in areas presenting inflammatory and/or infectious processes (e.g., papilloma, herpes). INNEA AQUA must not be used in association with other invasive treatments, * Avoid using in combination with any other concomitant therapies for same indication; * Patients who are using substances that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may, as with any injection, experience increased bruising or bleeding at treatment sites.